Ubrogepant - CISMeF

Preferred Label : Ubrogepant;

NCIt related terms : Ubrelvy;

NCIt definition : An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines. Upon oral administration, ubrogepant targets, binds to and blocks the activity of CGRP receptor. This prevents CGRP-mediated signaling. By blocking the CGRP-mediated pathways, ubrogepant is able to ease migraine symptoms, especially migraine headache pain. CGRP-mediated signaling plays a key role in migraine pathogenesis.;

UNII : AD0O8X2QJR;

InChIKey : DDOOFTLHJSMHLN-ZQHRPCGSSA-N;

CAS number : 1374248-77-7;

Drug name : Ubrelvy;

Molecule name : MK-1602;

NCI Metathesaurus CUI : CL554122;

Détails

Origin ID

C152790;

UMLS CUI

C4505936;

Automatic exact mappings (from CISMeF team)
- ubrogepant [ATC Code]
Currated CISMeF NLP mapping
- Ubrogepant (substance) [SNOMED CT concept]
- ubrogepant [MeSH Supplementary Concept]
- ubrogepant [MeSH concept]
See also inter- (CISMeF)
- Product containing ubrogepant (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing ubrogepant (medicinal product) [SNOMED CT concept]
- Ubrogepant (substance) [SNOMED CT concept]
- ubrogepant [MeSH Supplementary Concept]
- ubrogepant [ATC Code]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients